Skip to content
value.today

Xspray Pharma AB (publ)

XSPRAY.ST
$121 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$0 M
For year ending December-2025
Net income
$-17 M
Official annual report (ESEF)
Employees
—

Xspray Pharma AB (publ) in brief

Xspray Pharma AB (publ) is a listed company in the Biotechnology industry, based in Sweden. Its last known market value was $121 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $0 M and a net loss of $17 M. Its shares trade under the symbol XSPRAY.ST (Stockholm).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Xspray Pharma AB (publ) timeline

2 events, 2003–2017
  1. 2003
  2. 🏁
    · approximate
    Incorporated as Xspray Pharma AB (publ)
  3. 2017
  4. •
    Legal Entity Identifier issued
    LEI 549300NGRQCNZ3X4L157 registered.

Events of Xspray Pharma AB (publ) from the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$120 M$239 M$359 M$478 M20202021202220232024

World rank over time

▼ down 2,938 places since 2020
2020-01-01: #17516#17,51620202021-01-01: #11751#11,75120212022-01-07: #20458#20,45820222022-12-25: #20640#20,64020222023-07-30: #23571#23,57120232024-01-05: #20454#20,4542024

Rank in Sweden: #264 (Jan 2020) · #197 (Jan 2021) · #319 (Jan 2022) · #279 (Dec 2022) · #330 (Jul 2023) · #278 (Jan 2024)

Financial history

USD · fiscal years · source: official annual reports (ESEF)
RevenueNet income
Fiscal year ending Dec 2024: revenue $0M, net income $-27M$0MFY24Fiscal year ending Dec 2025: revenue $0M, net income $-17M$0MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$0M—$-16M$-17M—
Dec 2024$0M—$-27M$-27M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-20M$0M$-20M$-0.45—
Dec 2024$-21M$0M$-21M$-0.82—

Annual results

Revenue
$0 M
Operating income
$-16 M
Net income
$-17 M

For year ending December-2025 · source: official annual report (ESEF)

Balance sheet

Total assets
$84 M
Total liabilities
$18 M
Total equity
$66 M

As of December-2025

Mutual funds holding Xspray Pharma AB (publ)#

15 funds in 2 countries hold shares worth $2 M. Since their previous reports 15 added shares and 2 sold, buying $1 M net. By country: Sweden 12 ($2 M), USA 3 ($0 M).
Mutual funds holding Xspray Pharma AB (publ)
FundSharesValueOf the companyOf the fundChange in sharesReport
🇸🇪 Handelsbanken Norden Index CriteriaHandelsbanken Fonder AB465,015$1 M—0.02%+97%Jun 30, 2026
🇸🇪 Handelsbanken Sverige Index CriteriaHandelsbanken Fonder AB268,626$0 M—0%+10.0%Jun 30, 2026
🇸🇪 SEB Sverige IndexnäraSEB Funds AB187,391$0 M—0%+10.0%Jun 30, 2026
🇸🇪 Storebrand Sverige PlusStorebrand Asset Management AS128,557$0 M—0.01%+10.0%Jun 30, 2026
🇸🇪 PLUS Mikrobolag Sverige IndexISEC Services AB120,192$0 M—0.43%+9.4%Jun 30, 2026
🇸🇪 SEB Sverige IndexfondSEB Funds AB82,608$0 M—0%+10.0%Jun 30, 2026
🇸🇪 Storebrand Sverige Småbolag PlusStorebrand Asset Management AS57,255$0 M—0.03%+10.0%Jun 30, 2026
🇸🇪 Skandia Sverige ExponeringSkandia Fonder AB42,528$0 M—0%+11%Jun 30, 2026
🇸🇪 Skandia BalanseradSkandia Fonder AB22,930$0 M—0%+11%Jun 30, 2026
🇸🇪 Skandia Världen SverigeSkandia Fonder AB14,410$0 M—0%+11%Jun 30, 2026
🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP11,120$0 M—<0.01%+352%Jul 31, 2026
🇺🇸 International Sustainability Core 1 PortfolioDimensional Fund Advisors LP4,332$0 M—<0.01%newJul 31, 2026
🇺🇸 Dimensional VA International Small PortfolioDimensional Fund Advisors LP2,823$0 M—<0.01%+10.0%Jul 31, 2026
🇸🇪 Småbolag Sverige ExponeringSkandia Fonder AB2,250$0 M—0.01%+11%Jun 30, 2026
🇸🇪 Skandia FörsiktigSkandia Fonder AB1,921$0 M—0%+11%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 15 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Xspray Pharma AB (publ) scorecard#

Passes 0 of the 3 checks that could be worked out. Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.45 vs -0.82Diluted EPS -0.45 in fiscal 2025 against -0.82 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$17 MNet income -$17 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-28.6%-28.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial healthnot known
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (esef), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Xspray Pharma AB (publ): financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in SEK millions; per-share figures in SEK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Xspray Pharma AB (publ): statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue000000
Research and development11794022396.5
Selling, general and administrative1512041701105847
Operating income−157−287−182−133−98−53
Interest and finance income2.23.32.71.41.31.1
Interest expense and finance costs171.90.70.00.00.0
Income before tax−172−286−180−132−97−52
Income tax−0.1−0.2−0.0000
Net income including minority interests−171−286−180−132−97−52
Earnings per share, basic-4.46-8.62-6.76-6.25-5.03-3.05
Earnings per share, diluted-4.46-8.62-6.76-6.25-5.03-3.05
Shares, weighted average (basic)383327211917
Shares, weighted average (diluted)383327211918
Balance sheet
Cash and cash equivalents154208166120272326
Receivables3.84.04.22.42.52.7
Inventory2220448.66.20
Current assets183235218132282331
Property, plant and equipment7179——4543
Right-of-use (leased) assets2732382.53.55.2
Non-current assets586561547453341274
Total assets769796765585623605
Current liabilities2214640293020
Long-term debt1210————
Lease liabilities (non-current)2227320.61.22.9
Non-current liabilities14327320.61.22.9
Retained earnings−1,012−840−555−375−243−147
Shareholders' equity605623693556592583
Total equity605623693556592583
Total liabilities and equity769796765585623605
Cash-flow statement
Depreciation and amortization5.68.59.29.58.97.7
Cash from operating activities−193−222−203−110−52−48
Capital expenditure0−4.4−2.7−24−1.3−4.6
Cash from investing activities−29−42−66−135−106−97
Debt issued1209645———
Debt repaid−1000————
Shares issued161235298100100249
Cash from financing activities16830631694104260
Exchange-rate effect on cash−0.40.3−0.3———
Change in cash————−54116
ReportESEFESEFESEFESEFESEFESEF

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: ESEF annual reports (filings.xbrl.org) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

How Xspray Pharma AB (publ) compares in Biotechnology

  • Revenue$0 M · higher than 0% of 647

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Xspray Pharma AB (publ)🇸🇪$121 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 4, 2026

Figures from Official annual report (ESEF), value.today research, GLEIF register.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Xspray Pharma AB (publ)? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Xspray Pharma AB (publ)'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Xspray Pharma AB (publ)? Suggest a correction